

Product Datasheet

Recombinant Human Vascular Endothelial Growth Factor - 165 (rhVEGF₁₆₅)

Description

Source:	<i>E.coli</i> -derived, purified by proprietary chromatographic techniques Ala27-Arg191, Accession # P15692-4
Structure/ Form:	Disulfide-linked homodimer, non-glycosylated, 165 amino acids
Predicted Molecular Mass:	38 kDa (dimer)

Specifications

SDS-PAGE:	39 kDa, non-reducing conditions; 21 kDa, reducing conditions
Activity:	Measured in a cell proliferation assay using HUVECs (human umbilical vein endothelial cells) [1]. The K _{0.5} is typically 5-20 pM.
Purity:	> 95 %, determined by SDS-PAGE
Endotoxin Level:	< 0.05 EU per 1 µg of the protein by the LAL method.
Formulation:	Lyophilized from a 0.2 µm filtered concentrated (100 µg/ml) solution in PBS buffer (pH 7.4).

Preparation and Storage

Solubility:	It is recommended to reconstitute the lyophilized VEGF in sterile H ₂ O, which can be further dialyzed to other aqueous solutions.
Shipping:	The product is shipped at ambient temperature. Upon receipt store it immediately at the temperature recommended below.
Stability & Storage:	Please avoid freeze-thaw cycles. <ul style="list-style-type: none">• 2-8 °C: 4 weeks after reconstitution• -20 - -70 °C: 3 months after reconstitution• -20 - -70 °C: 12 months as supplied

References:

- [1] K. Zurlinden, M. Laub, D.S. Dohle, K.P. Jennissen (2012), Immobilization and Controlled Release of Vascular (VEGF) and Bone Growth Factors (BMP-2) on Bone Replacement Materials, Biomed Tech (57). 989-992

For research use only.

Not for human use.